# FLAP

## 5-lipoxygenase-activating protein; 5-LO activating protein

FLAP (Arachidonate 5-lipoxygenase-activating protein) is an integral membrane protein, which facilitates the transfer of the substrate arachidonic acid (AA) to 5-lipoxygenase (5-LO) to produce leukotrienes (LTs), and is shown to be indispensable for cellular LT biosynthesis. FLAP transfers arachidonic acid to 5-LOX protein, thereby enabling this enzyme to efficiently produce oxidized lipid products (mainly eicosanoids) that are important in cell growth, differentiation and death particularly apoptosis.

# FLAP Inhibitors

## (S)-BI 665915

Cat. No.: HY-12995A

(S)-BI 665915 is an orally active oxadiazole-containing **5-lipoxygenase-activating protein (FLAP)** inhibitor with an $IC_{50}$ of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an $IC_{50}$ of 45 nM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## AM103

Cat. No.: HY-14163

AM 103 is a potent and selective **FLAP** inhibitor, with an $IC_{50}$ value of 4.2 nM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## AM679

Cat. No.: HY-14460

AM679 is a potent, selective **5-lipoxygenase-activating protein (FLAP)** inhibitor with an $IC_{50}$ of 2 nM in a human FLAP membrane binding assay.



**Purity:** 99.72%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Atuliflapon

(AZD5718)

Cat. No.: HY-122908

Atuliflapon (AZD5718) is an orally active inhibitor of **FLAP (5Lipoxygenase activating protein)**, with an $IC_{50}$ of 2 nM. Atuliflapon is used in the study for coronary artery disease.



**Purity:** 98.14%
**Clinical Data:** Phase 2
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Diflapolin

Cat. No.: HY-128171

Diflapolin is a highly active dual 5-lipoxygenase-activating protein **(FLAP)**/soluble epoxide hydrolase **(sEH)** inhibitor with marked anti-inflammatory efficacy and high target selectivity.



**Purity:** 99.42%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Fiboflapon

(GSK2190915; AM-803)

Cat. No.: HY-15874

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an $IC_{50}$ of 76 nM for inhibition of **LTB4** in human blood.



**Purity:** 98.54%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Fiboflapon sodium

(GSK2190915 sodium salt; AM-803 sodium)

Cat. No.: HY-15874A

Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an $IC_{50}$ of 76 nM for inhibition of **LTB4** in human blood.



**Purity:** 99.91%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## MK-886

(L 663536)

Cat. No.: HY-14166

MK-886 (L 663536) is a potent, cell-permeable and orally active **FLAP** ($IC_{50}$ of 30 nM) and **leukotriene biosynthesis** ($IC_{50}$s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive **PPARα** antagonist and can induce **apoptosis**.



**Purity:** 99.74%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Quiflapon

(MK-591)

Cat. No.: HY-10037

Quiflapon (MK-591) is a selective and specific **5-lipoxygenase-activating protein (FLAP)** inhibitor with an $IC_{50}$ of 1.6 nM in a FLAP binding assay.



**Purity:** 99.44%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Quiflapon sodium

(MK-591 sodium)

Cat. No.: HY-50714

Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (**FLAP**) inhibitor. Quiflapon sodium is an orally active **Leukotriene biosynthesis** inhibitor. Induces **apoptosis**.



**Purity:** 98.65%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Veliflapon

**(BAY X 1005; DG-031)** **Cat. No.**: HY-14165

Veliflapon (BAY X 1005; DG-031) is an orally active and selective **5-lipoxygenase activating protein (FLAP)** inhibitor. Veliflapon inhibits the synthesis of the **leukotrienes B4** and **C4**.




**Purity:** 99.16%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg